Moreover, a pharmacological inhibitor of IRE1α, B109, was reported to suppress CLL tumor cell progression in a murine model and to sensitize human CLL cells to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib [164]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.